HomeCompareITOS vs NNN

ITOS vs NNN: Dividend Comparison 2026

ITOS yields 19.70% · NNN yields 5.68%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ITOS wins by $46.2K in total portfolio value
10 years
ITOS
ITOS
● Live price
19.70%
Share price
$10.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$71.7K
Annual income
$6,528.88
Full ITOS calculator →
NNN
NNN REIT Inc.
● Live price
5.68%
Share price
$41.89
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.6K
Annual income
$2,637.42
Full NNN calculator →

Portfolio growth — ITOS vs NNN

📍 ITOS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodITOSNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ITOS + NNN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ITOS pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ITOS
Annual income on $10K today (after 15% tax)
$1,674.88/yr
After 10yr DRIP, annual income (after tax)
$5,549.55/yr
NNN
Annual income on $10K today (after 15% tax)
$482.93/yr
After 10yr DRIP, annual income (after tax)
$2,241.81/yr
At 15% tax rate, ITOS beats the other by $3,307.74/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ITOS + NNN for your $10,000?

ITOS: 50%NNN: 50%
100% NNN50/50100% ITOS
Portfolio after 10yr
$48.6K
Annual income
$4,583.15/yr
Blended yield
9.42%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

ITOS
Analyst Ratings
3
Buy
5
Hold
Consensus: Hold
Price Target
$18.20
+79.3% upside vs current
Range: $9.00 — $46.00
Altman Z
1.6
Piotroski
1/9
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+7.3% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ITOS buys
0
NNN buys
0
No recent congressional trades found for ITOS or NNN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricITOSNNN
Forward yield19.70%5.68%
Annual dividend / share$2.00$2.38
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%8.6%
Portfolio after 10y$71.7K$25.6K
Annual income after 10y$6,528.88$2,637.42
Total dividends collected$40.5K$13.7K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldHold
Analyst price target$18.20$44.93

Year-by-year: ITOS vs NNN ($10,000, DRIP)

YearITOS PortfolioITOS Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$12,670$1,970.44$10,737$617.02+$1.9KITOS
2$15,891$2,333.31$11,577$710.93+$4.3KITOS
3$19,738$2,734.88$12,538$822.59+$7.2KITOS
4$24,294$3,174.78$13,645$956.06+$10.6KITOS
5$29,647$3,652.03$14,925$1,116.51+$14.7KITOS
6$35,887$4,165.10$16,415$1,310.57+$19.5KITOS
7$43,111$4,711.97$18,158$1,546.77+$25.0KITOS
8$51,419$5,290.18$20,213$1,836.20+$31.2KITOS
9$60,916$5,896.86$22,649$2,193.37+$38.3KITOS
10$71,709$6,528.88$25,558$2,637.42+$46.2KITOS

ITOS vs NNN: Complete Analysis 2026

ITOSStock

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Full ITOS Calculator →

NNNREIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this ITOS vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ITOS vs SCHDITOS vs JEPIITOS vs OITOS vs KOITOS vs MAINITOS vs ADCITOS vs EPRTITOS vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.